Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

Halliho Sep. 7 at 8:23 AM

$ABCL https://www.zacks.com/stock/news/2669692/myriad-genetics-mygn-q2-earnings-and-revenues-surpass-estimates?cid=CS-STOCKTWITS-HL-tale_of_the_tape|yseop_template_4-2669692&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_513_2669692

0 · Reply

Eurofighter Sep. 6 at 7:04 AM

$SOFI do your DD on $ABCL This could become a Jupiter rocket

0 · Reply

Stocktradesmoon Sep. 6 at 5:49 AM

$ABCL 👀

1 · Reply

Stocktradesmoon Sep. 6 at 3:00 AM

$ABCL Bottom line thesis from $ABCL ‘s today’s WF conference is they are doing deliberate, capital-efficient pivot from being a pure discovery engine toward a hybrid platform+pipeline company. $ABCL will preserve p/ship revenue while building optionality & manufacturing capabilities.

0 · Reply

Stocktradesmoon Sep. 6 at 2:30 AM

$ABCL It still amazes me how much people panic when one of their stocks pullback. Like this isn’t a surprise. If you’re new to investing, get used to it.

1 · Reply

estatebuyersmia Sep. 6 at 2:20 AM

$ABCL There is nothing in the forseeable future that will propel the stock higher other than a partnership for its exzema drug and that wont happen until mid 2026 when the phase 1 trial results are posted. I think the stock pulls back here until than, my opinion of course.

1 · Reply

Stocktradesmoon Sep. 6 at 1:45 AM

$ABCL

0 · Reply

Stocktradesmoon Sep. 6 at 1:45 AM

$ABCL $ABCL CFO Andrew Booth discusses @AbCelleraBio ’s differentiation and their “best-in-world” capabilities for difficult to find therapeutic antibodies:

0 · Reply

Ed_Ng Sep. 5 at 10:36 PM

$ABCL you were saying this is your investment.. and should be 2 digits bla bla. Now you are saying this is for trade (you were laughing at me when I said this). What a 🤡

2 · Reply

Grouphome Sep. 5 at 10:35 PM

$ABCL $GRBK $IBP $PRME

0 · Reply

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 25 days ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 4 weeks ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 weeks ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 3 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 4 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 4 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 4 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 4 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 4 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 5 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 6 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 8 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 8 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 9 months ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 10 months ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 10 months ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 10 months ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 11 months ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 11 months ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 1 year ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Feb 23, 2024, 4:30 PM EST - 1 year ago

AbCellera Announces Resignation of Board Member

Feb 22, 2024, 8:15 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in March

Feb 20, 2024, 11:45 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript

Feb 20, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2023 Business Results

Jan 23, 2024, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Dec 20, 2023, 4:05 PM EST - 1 year ago

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

Halliho Sep. 7 at 8:23 AM

0 · Reply

Eurofighter Sep. 6 at 7:04 AM

$SOFI do your DD on $ABCL This could become a Jupiter rocket

0 · Reply

Stocktradesmoon Sep. 6 at 5:49 AM

$ABCL 👀

1 · Reply

Stocktradesmoon Sep. 6 at 3:00 AM

0 · Reply

Stocktradesmoon Sep. 6 at 2:30 AM

$ABCL It still amazes me how much people panic when one of their stocks pullback. Like this isn’t a surprise. If you’re new to investing, get used to it.

1 · Reply

estatebuyersmia Sep. 6 at 2:20 AM

1 · Reply

Stocktradesmoon Sep. 6 at 1:45 AM

$ABCL

0 · Reply

Stocktradesmoon Sep. 6 at 1:45 AM

$ABCL $ABCL CFO Andrew Booth discusses @AbCelleraBio ’s differentiation and their “best-in-world” capabilities for difficult to find therapeutic antibodies:

0 · Reply

Ed_Ng Sep. 5 at 10:36 PM

$ABCL you were saying this is your investment.. and should be 2 digits bla bla. Now you are saying this is for trade (you were laughing at me when I said this). What a 🤡

2 · Reply

Grouphome Sep. 5 at 10:35 PM

$ABCL $GRBK $IBP $PRME

0 · Reply

estatebuyersmia Sep. 5 at 9:04 PM

$ABCL I own many stocks, mostly companies that sell products or services. This was a Biotech stock with great promise but earnings are a long way off. It should be handled as a trade and not a fundamental investment situation. Ill be back if the stock pulls back.

1 · Reply

NVDAMillionaire Sep. 5 at 8:40 PM

$ABCL Brilliant piece that captures ABCL's situation perfectly. So if you want to update your understanding of ABCL or get to know ABCL better, this is essential reading. https://beyondspx.com/quote/ABCL/abcellera-pivoting-to-pipeline-backed-by-tech-and-capital-abcl#analysis

1 · Reply

estatebuyersmia Sep. 5 at 6:43 PM

$ABCL SWAP $ABCL FOR $RXRX, I DID...

3 · Reply

estatebuyersmia Sep. 5 at 6:03 PM

$ABCL Obviously the market is telling you something here....

0 · Reply

TheDrunkTrader69 Sep. 5 at 4:54 PM

$ABCL Sorry fellas i needed the liquidity, I hope this keeps going higer and higher, and I regret selling. But I'm ready to retire soon and dont want too many tickers to watch , consolating down to a few only.

2 · Reply

Brb579 Sep. 5 at 4:49 PM

$ABCL

1 · Reply

Ed_Ng Sep. 5 at 4:41 PM

$ABCL $OSTX haha another BS. Like I said many times before, don't listen to these pumpers, they are liars

2 · Reply

Brb579 Sep. 5 at 4:41 PM

$ABCL jesus man wtf...

1 · Reply

DeMampCamp Sep. 5 at 4:35 PM

$ABCL If you’re here looking for meme-stock hype, this isn’t the place. Go join the other degenerates at OPEN or NEON if you want that circus. ABCL is for serious long-term investors — it’s still under the radar, and that’s exactly why it’s worth paying attention to. - Cheers and happy Friday to all!

1 · Reply

TheDrunkTrader69 Sep. 5 at 4:27 PM

$ABCL Truth be told I already sold, buying at 2 and sell at 4.50 is fine with me doesnt seem like its ready to really fly yet, I rebought into $OSTX @ 2 waiting on the boom, great company with high potential, good luck everyone 👍

1 · Reply

estatebuyersmia Sep. 5 at 4:20 PM

$ABCL Look ABCL is a great company but it needs a catalyst to move higher and I dont see one. I hope it retraces so I can reenter.

1 · Reply

Ed_Ng Sep. 5 at 4:20 PM

$ABCL I have no friend here. "rip" and rest in peace. This chart is clearly head and shoulders

1 · Reply

Market Cap	1.26B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	4,173,500
Avg Vol	5,840,208
Day's Range	N/A - N/A
Shares Out	298.83M
Stochastic %K	54%
Beta	0.64
Analysts	Strong Sell
Price Target	$9.29